Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare CED Not A Good Fit With Groundbreaking Products, Drug Firms Argue

Executive Summary

In comments on CMS’ recent draft guidance on Medicare coverage with evidence development, Onyx Pharmaceuticals recommends that cutting edge therapies with postmarketing commitments like its cancer drug Kyprolis should be exempted, and Amyvid marketer Lilly says CED is not appropriate for radiopharmaceuticals.

You may also be interested in...



Medicare To Use Evidence Development For Off-Label Drug Use? CMS Guidance Unclear

CMS’ guidance on its “coverage with evidence development” policy for Medicare Part B does not elaborate on the scope of its application to off label drug use, only stating the agency could apply CED to drugs that have received FDA approval for at least one indication.

Specialty Drug Costs Should Be Left To Market-Based Solutions – PBMs

CVS Caremark and Express Scripts agree that direct government involvement in pricing and coverage policies is not needed to contain the high cost of specialty drugs such as Gilead’s Sovaldi.

Onyx Kyprolis Launch Strategy Includes Speedy Delivery, Premium Price

Onyx is pricing new myeloma drug carfilzomib at $9,950 per cycle, 65% higher than Takeda/Millennium’s pioneering proteasome inhibitor Velcade. Launch plans include financial assistance for providers, comprehensive patient assistance program and transition for expanded access patients to commercial drug.

Topics

Related Companies

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel